Familial eosinophilia: A benign disorder?

Blood

Volumn 103, Issue 11, 2004, Pages 4050-4055

  Klion, Amy D ^a,b   Law, Melissa A ^a   Riemenschneider, William ^a   McMaster, Mary Lou ^a   Brown, Margaret R ^a   Horne, McDonald ^a   Karp, Barbara ^a   Robinson, Michael ^a   Sachdev, Vandana ^a   Tucker, Eben ^a   Turner, Maria ^a   Nutman, Thomas B ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; INTERLEUKIN 2 RECEPTOR; MAJOR BASIC PROTEIN; NEUROTOXIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CELL ACTIVATION; CELL STRUCTURE; CELL SURFACE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EOSINOPHIL; EOSINOPHILIA; FAMILIAL DISEASE; FAMILIAL EOSINOPHILIA; FAMILY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MEDICAL ASSESSMENT; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; TRANSMISSION ELECTRON MICROSCOPY;

EID: 2542494041     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-11-3850     Document Type: Article

References (26)

1. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759-2779.
2. Chusid MJ, David DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine. 1975;54:1-27.
3. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
4. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101:4660-4666.
5. Aractingi S, Janin A, Zini JM, et al. Specific mucosal erosions in the hypereosinophilic syndrome: evidence for eosinophil protein deposition. Arch Dermatol. 1996;132:535-541.
6. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. The idiopathic hypereosinophilic syndrome. Ann Intern Med. 1982;97:78-92.
7. Tai P, Spry CJF, Olsen EGJ, Ackerman SJ, Dunnette S, Gleich GJ. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet. 1987;1:643-647.
8. Lin AY, Nutman TB, Kaslow D, et al. Familial eosinophilia: clinical and laboratory results on a U.S. kindred. Am J Med Genet. 1998;76:229-237.
9. Rioux JD, Stone VA, Daly MJ, et al. Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33. Am J Hum Genet. 1998;63:1086-1094.
10. Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341:1112-1120.
11. Allanson JE. Objective techniques for craniofacial assessment: what are the choices? Am J Med Genet. 1997;70:1-5.
12. Farkas LG, Anthropometry of the Head and Face. 2nd ed. New York, NY: Raven Press; 1994.
13. Garn SM, Smith BH, La Velle M. Applications of pattern profile analysis to malformations of the head and face. Radiology. 1984;50:683-690.
14. Wallen N, Kita H, Weiler D, Gleich GJ. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol. 1991;147:3490-3495.
15. Peters MS, Gleich GJ, Dunnette SL, Fukuda T. Ultrastructural study of eosinophils from patients with the hypereosinophilic syndrome: a morphological basis of hypodense eosinophils. Blood, 1988;71:780-785.
16. Dvorak AM, Weller PF. Ultrastructural analysis of human eosinophils. Chem Immunol. 2000;76:1-28.
17. Bochner BS. Systemic activation of basophils and eosinophils: markers and consequences. J Allergy Clin Immunol. 2000;106:S292-S302.
18. Tachimoto H, Bochner BS, The surface phenotype of human eosinophils. Chem Immunol. 2000;76:45-62.
19. Wassom DL, Loegering DA, Solley GO, et al. Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia. J Clin Invest. 1981;67:651-661.
20. Owen WF, Rothenberg ME, Petersen J, et al. Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J Exp Med. 1989;170:343-348.
21. Committee TISoAaAiCIS. Worldwide variation in the prvalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema. Lancet. 1998;351:1225-1232.
22. Bobbio-Pallavicini E, Confalonieri M, Tacconi F, et al. Study of release of eosinophil cationic proteins (ECP and EPX) in the hypereosinophilic syndrome (HES) and other hypereosinophilic conditions. Panminerva Med. 1998;40:186-190.
23. Mawhorter SD, Stephany DA, Ottesen EA, Nutman TB. Identification of surface molecules associated with physiologic activation of eosinophils: application of whole blood flow cytometry to eosinophils. J Immunol. 1996;156:4851-4858.
24. Hartnell A, Robinson DS, Kay AB, Wardlaw AJ. CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines. Immunology. 1993;80:281-286.
25. Matsumoto K, Appiah-Pippim J, Schleimer RP, Bickel CA, Beck LA, Bochner BS. CD44 and CD69 represent different types of cell-surface activation markers for human eosinophils. Am J Resp Cell Mol Biol. 1998;18:860-866.
26. Nopp A, Lundahl J, Hallden G. Quantitative, rather than qualitative, differences in CD69 upregulation in human blood eosinophils upon activation with selected stimuli. Allergy. 2000;55:148-156.